Cardiovascular Risk and Subclinical Atherosclerosis in Senegalese Patients with Rheumatoid Arthritis: A Cross-Sectional Study in a Single Centre

Baidy Sy Kane1, Awa Cheikh Ndao1, Abdourahmane Samba2, Mame Madiguène Ka3, Maïmouna Sow1, Fatou Aw3, Mohamed Dieng1, Souhaïbou Ndongo1, Mouhamadou Bamba Ndiaye3, Maboury Diao3, Abdoulaye Pouye1

1Department of Internal Medicine, Le Dantec Teaching Hospital, Cheikh Anta DIOP University, Dakar, Senegal
2Biochemistry Laboratory, Le Dantec Teaching Hospital, Cheikh Anta DIOP University, Dakar, Senegal
3Department of Cardiology, Le Dantec Teaching Hospital, Cheikh Anta DIOP University, Dakar, Senegal

Email: ng.mostafa.ibrahim2010@gmail.com

Abstract

Introduction: Rheumatoid arthritis (RA) is associated with increasing of cardiovascular (CV) morbidity and mortality due to accelerated atherosclerosis. Several studies showed also the increasing of the prevalence of subclinical atherosclerosis, but there are little data from sub-Saharan Africa. The aim of our study was to assess the prevalence of cardiovascular risk factors, subclinical carotid atherosclerosis and the ability of the Systematic Coronary Risk Estimation (SCORE) modified by European League Against Rheumatism (EULAR) to predict the high CV risk in our patients. Patients and Method: We conducted a cross sectional study in Senegalese patients with RA. The RA was retained according to 2010 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) criteria. Patients with RA were assessed in a clinical research consultation. Results: We included 50 RA patients. The mean age was 44 years (+/- 12.37) and the sex-ratio was 0.06. The frequency distribution of traditional cardiovascular risk factors was: hypertension (HT) (30%), diabetes mellitus (6%), smoking (2%), no-exercise (22%), obesity (16%), metabolic syndrome (8%). Fifty-eight percent of patients were classified at low cardiovascular risk according to mSCORE. 51.7% of patients classified as moderate-risk according to mSCORE, were reclassified as high cardiovascular risk according to carotid ultrasound evaluation (gold-standard). The sensitivity of the mSCORE in the prediction of high CV risk was low at 20%. In the present study, the prevalence of carotid subclinical atherosclerosis was 20%. Age (>45 years) and HT
Conclusion: In the present study, the prevalence of atherosclerosis in RA patients was higher than expected frequency in comparison with the prevalence in Senegalese general population. We showed that CV risk was underestimated by mSCORE which had a low sensitivity in the prediction of high risk. We showed also the importance of carotid ultrasound for an appropriate stratification of the risk.

Keywords
Rheumatoid Arthritis, Subclinical Atherosclerosis, Africa South of the Sahara

1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by progressive joint destruction associated with extra-articular manifestations affecting different internal organs [1] [2].

RA is the most common chronic inflammatory joint disease and occurs throughout the world, in all ethnic groups, with a prevalence that ranges from 0.3% to 1.2% [2].

RA is associated with increasing of cardiovascular (CV) morbidity and mortality due to accelerated atherosclerosis. Thus, there is evidence of close relationship between RA and CV events such as stroke, congestive heart-failure and myocardial infarction [1] [3]-[16].

Several studies showed also the increasing of the prevalence of subclinical atherosclerosis, using different modalities including carotid ultrasound to detect carotid plaques.

Subclinical atherosclerosis may additionally identify the patients with high risk of CV events [17].

The high incidence of CV morbidity and mortality may due to higher prevalence of traditional cardiovascular risk factors and the role of systemic inflammation [11].

However, there are paucity data about CV risk and RA in sub-Saharan Africa [10] [18].

We conducted a cross sectional study in Senegalese patients with RA to assess the prevalence of cardiovascular risk factors, subclinical carotid atherosclerosis and the ability of the Systematic Coronary Risk Estimation (SCORE) modified by European League Against Rheumatism (EULAR) to predict the high CV risk in our patients.

2. Patients and Methods
2.1. Study Population
We conducted a cross sectional study in the Department of Internal Medicine of our institution during the period from July 03, 2017 to December 31, 2018.
We included patients followed for RA that met the 2010 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) criteria [19]. RA patients with other autoimmune diseases or a history of clinical cardiovascular events (such as myocardial infarction, stroke, or peripheral arterial disease) were not included.

2.2. Clinical and Laboratory Assessment

Patients with RA were assessed in a clinical research consultation.

The following data were refined:
- General data such as age, gender, existence of smoking, alcohol consumption, family history of early cardiovascular disease among 1st degree relatives.
- The existence of a cardiovascular risk factor: smoking, overweight (defined by body mass index > 25 kg/m²) or obesity (defined by a body mass index > 30 kg/m²), waist circumference measurement, high blood pressure (HBP), diabetes-mellitus (DM), dyslipidemia according to their standard definitions.
- The disease duration, the diagnosis delay of RA, the clinical pattern, the disease activity by the disease activity score 28 with CRP (DAS-28 CRP) at the inclusion of this study, the duration of corticosteroid therapy, the daily dose and background therapy RA [20]. Active disease was defined by DAS-28 ≥ 2.6 [20].
- The following biological investigations were carried out (CRP, creatinine and calculation of glomerular filtration rate, fasting blood glucose, total cholesterol, HDL cholesterol, LDL cholesterol, Uricemia).
- SCORE: We calculated the SCORE and we also applied a multiplicator factor of 1.5 for the modified SCORE (mSCORE) according to EULAR guidelines [21]. We defined the different groups of risk: low risk (<1%), moderate risk (1% - 5%), high risk (5% - 10%), very high risk of CV mortality (>10%).
- The immunological patterns such as the results of rheumatoid factor (RF) or anti-cyclic citrullinated peptides (CCP) were specified from the observation files.

2.3. Carotid Ultrasound

The vascular ultrasound was performed by a device Esaotemylab alpha with a 3 - 13 MHz linear probe. The measurement of the carotid intima-media thickness (cIMT) was performed at the common carotid artery 1.5 cm from the carotid bulb by a trained ultrasonographer and an automated measurement software (RFQIMT). Carotid atherosclerosis was defined by the existence of plaques or cIMT ≥ 0.9 mm [22].

2.4. Statistical Analysis

The data were recorded and analyzed using SPSS 23.0 software.
The results were expressed as a mean (+/− standard deviation) for the continuous variables and as percentages for the categorical variables.

Means were compared using t Student test, and comparisons between categorical measures were made using chi2 test. The p-value < 0.05 was considered statistically significant.

The gold standard for the definition of high-cardiovascular risk was cIMT ≥ 0.90 mm or atherosclerosis plaques. We used this definition for the derivation of sensitivity of mSCORE to the prediction of the high cardiovascular risk.

2.5. Ethics

The study was conducted in accordance with the Helsinki Declaration. An informed written consent has been obtained for all investigations on patients of the study.

3. Results

We included 50 patients followed for RA. These were 47 women and 03 men with a sex ratio of 0.06. The mean age was 44 years (+/− 12.37).

The mean duration of disease progression was 76.49 months (+/− 87.2) and the mean diagnostic delay was 38.27 (+/− 78.2).

Clinically, the mean number of painful joints was 5.6 (+/− 7.9) and the mean number of swollen joints was 5.02 (+/− 5.4). Joint deformities were noted in 66% of patients and extra-articular manifestations in 64% of cases.

The mean DAS-28 was 3.8 (+/− 1.2).

Anti-CCP was positive in 96.6% of patients and RF in 66.6% of cases. Clinical, immunological and therapeutic data are summarized in Table 1.

The frequency distribution of traditional cardiovascular risk factors was: hypertension (HT) (30%), diabetes-mellitus (6%), smoking (2%), no-exercise (22%), obesity (16%), metabolic syndrome (8%) (Table 2).

The distribution of the cardiovascular risk level by SCORE and mSCORE has been presented in Table 3. Fifty-eight percent had a low risk according to SCORE and mSCORE. Twenty-eight percent had moderate risk and eight percent had high risk according to mSCORE.

The mean cIMT was 0.63 mm (+/− 1.36). 10 patients (20%) had carotid atherosclerosis.

Eight patients (out of 14% or 51.7%) classified as moderate-risk according to mSCORE, were reclassified as high cardiovascular risk according to carotid ultrasound evaluation (gold-standard).

The sensitivity of the mSCORE equation in cardiovascular high-risk prediction was 20%, similar to the SCORE.

In the present study, only age (>45 years, p-value: 0.01) and hypertension (0.009) were correlated with carotid atherosclerosis (Table 4).

4. Discussion

RA is the first chronic rheumatism in the general population [2] [23] [24]. This
Table 1. Rheumatoid arthritis-related factors at in inclusion.

| Variables                              | Results: Mean (+/- SD) or % |
|----------------------------------------|-----------------------------|
| Mean disease duration (months)         | 76.49 (+/- 87.2)            |
| Mean diagnostic delay (months)         | 38.27 (+/- 78.2)            |
| Number of painful joints               | 5.6 (+/- 7.9)               |
| Number of swollen joints               | 5.02 (+/- 5.4)              |
| Clinical tenosynovitis (%)             | 27.7%                       |
| Number of night awakening              | 0.86 (+/- 1.8)              |
| Morning stiffness duration (minutes)   | 30.4 (+/- 37.7)             |
| Joints deformities (%)                 | 66%                         |
| DAS 28 CRP (mean value)                | 3.8 (+/- 1.2)               |
| Extra-articulaire manifestations (%)   | 64%                         |
| Positivity of Rheumatoid Factor        | 20/30 (66.6%)               |
| Positivity of anti-CCP                 | 29/30 (96.6%)               |
| Prednisone                             | 98%                         |
| Methotrexate                           | 70%                         |
| Sulfasalazine                          | 28%                         |
| Hydroxychloroquine                     | 50%                         |
| Patients followed by up to 1 DMARD     | 34%                         |

DAS 28-CRP: disease activity score 28 with C-reactive protein; anti-CCP: anti-cyclic citrullinated peptides antibodies; DMARD: disease modifying anti-rheumatic drug.

Table 2. Cardiovascular risk factors at the inclusion.

| Variables                               | Results (%) |
|-----------------------------------------|-------------|
| Patients with prior history of DM       | 4           |
| Patients with prior history of HT       | 14          |
| HT (at the inclusion)                   | 32          |
| Abnormal serum glucose                  | 4           |
| DM                                      | 6           |
| Dyslipidemia                            | 30          |
| Tobacco Smoking                         | 2           |
| Alcohol consumption                     | 0           |
| No exercise                             | 22          |
| Obesity                                 | 16          |
| High waist circumference, men (>102)    | 0           |
| High waist circumference, women (>88 cm)| 21.2        |
| Metabolic syndrome                      | 8           |

DM: diabetes-mellitus; HT: Hypertension.
Table 3. Cardiovascular risk stratification.

| Cardiovascular Risk          | SCORE (%)* | mSCORE (%)* |
|-----------------------------|------------|-------------|
| Low (<1%)                   | 58         | 58          |
| Moderate (≥1% et <5%)       | 30         | 28          |
| High-risk (≥5% et <10%)     | 6          | 8           |
| Very high-risk (≥10%)       | 0          | 0           |
| Not applicable*             | 6          | 6           |

SCORE: Systematic coronary risk estimation; mSCORE: Systematic Coronary risk estimation modified by European league against rheumatism. *Diabetes-mellitus.

Table 4. Correlation between carotid atherosclerosis and disease-related or cardiovascular-risk factors.

| Variables                              | p-value |
|----------------------------------------|---------|
| Age (<45 ans/≥45 ans)                  | 0.01    |
| Sex                                    | 0.43    |
| Diagnostic delay (<12 mois/≥12 mois)   | 0.35    |
| No-exercice                            | 0.44    |
| Hypertension                           | 0.009   |
| Obesity                                | 0.68    |
| Dyslipidemia                           | 0.84    |
| Metabolic syndrome                    | 0.36    |
| Disease activity                       | 0.14    |
| Extra-articulaire manifestations       | 0.28    |
| Joints-deformities                     | 0.72    |
| Corticosteroid duration (<24 mois/≥24 mois) | 0.13 |
| Corticosteroid dose, daily (<10 mg/j/≥10 mg/j) | 0.87 |
| Rheumatoid factor                      | 0.53    |
| Anti-CCP                               | 0.17    |

anti-CCP: anti-cyclic citrullinated peptides antibodies.

chronic inflammatory disease is associated with an increased risk of mortality, as compared with general population, mainly due to cardiovascular events [1] [3]-[16].

The mechanisms leading to accelerated atherosclerosis and increased rate of CV events are complex including traditional CV factors, systemic chronic inflammation; genetic compound; RA therapies such as corticosteroids [16] [25].

In the present study, we assessed the prevalence of carotid subclinical atherosclerosis and we found a lower prevalence when compared with other series. Ambrosino et al., reported a meta-analysis of 59 observational studies and showed an increased prevalence of atherosclerosis in RA patients with a prevalence of 32.7% [26]. Two studies were also especially conducted in sub-Saharan
Africa about RA and subclinical atherosclerosis [9] [18]. They found also a high prevalence when compared with our study, 35.5% in black patients in South Africa and 32% in Kinshasa (Democratic Republic of Congo) [9] [18]. However, in Italia and India, the prevalence of subclinical atherosclerosis was slightly lower to this present study, respectively 16% and 15.2% [16] [17]. This could suggest differences due to environmental and genetic factors. Indeed, several studies have confirmed the role of genetic factors in the development of atherosclerosis in RA. Thus, alleles from the \( HLA-DRB1 \) genes especially the \( HLA-DRB1^*0404 \) allele were associated with dysfunctional endothelial and presence of atheroma plaques [25] [27]. Other genes variants were also associated with cIMT in RA patients [4].

In the present study, the prevalence of atherosclerosis in RA patients was higher than expected frequency. In the Senegalese general population, the prevalence of subclinical atherosclerosis was estimated at 6.8% [28].

Atherogenesis in RA is mediated by traditional CV risk factors and disease-related factors particularly high-grade inflammation, disease duration or RA therapies such as corticosteroids. One of the important finding of our study was the results about relations between subclinical atherosclerosis in RA patients and these traditional CV risk factors and disease specific factors. In the present study, only age (>45 years) and HT was correlated to carotid atherosclerosis. Several studies have demonstrated the impact of age in the genesis and development of atherosclerosis [18]. Age plays a role in the appearance of vascular lesions induced by oxidative stress and inflammation. These lesions can lead to the development of atherosclerosis also other CV risk factors such as HT [18]. HT was the most important CV risk factor associated with RA in our study as well as in South Africa [11]. An increased prevalence of HT was also reported in black patients without RA in sub-Saharan Africa [11]. Mulumba et al., reported also an association with older age and HT [18]. Ruscitti et al., showed also a correlation between atherosclerosis and HT [16]. Despite the well-known implication of other CV risk factors such as diabetes-mellitus, smoking, dyslipidemia, or metabolic syndrome, our study failed to demonstrate the expected association among these factors and subclinical atherosclerosis. Additionally, any RA-related factor was associated with carotid atherosclerosis, including disease-duration, disease-activity or joint-deformities. This suggests that our study had potentially limited power to identify significant statistic association between these factors and subclinical atherosclerosis.

Adequate stratification of CV risk is an important step in the management of RA patients [22]. Therefore, we evaluated the ability of the mSCORE in the prediction of the high-CV risk in comparison with carotid ultrasound. Indeed, previous studies have confirmed that a cIMT > 0.90 mm is indicative of atherosclerosis and increased of CV disease [22]. Carotid plaques are also predictors of coronary artery disease progression and closely associated with coronary artery disease [22]. We showed in this present study that the sensitivity of the mSCORE in the prediction of high risk was low, and the CV risk was underestimated by
mSCORE in patient with RA. These results corroborate those of Corrales et al. [22]. However, there are differences in the determination. Corrales et al. followed the 2009 EULAR recommendations for CV risk management which suggested a multiplication factor 1.5 to calculated total CV disease risk (SCORE) if the patient fulfilled certain disease-specific criteria (i.e. disease duration of >10 years, RF or ACPA positivity and the presence of certain extra-articular manifestations) [22] [29]. In our study, mSCORE was obtained after application of the multiplication factor 1.5 in all RA patients according to the 2015/2016 update EULAR guidelines [21].

The main limitations of our study were the cross-sectional design without controls subjects and his small sample size. We did not perform a power analysis prior to the initiation of the study. The sample size was retained according to the limits of means of explorations. However, it’s the first study who described the frequency of subclinical atherosclerosis in Senegalese patients with RA. Carotid ultrasound should be proposed for a best CV risk assessment especially in RA patients with moderate CV risk.

5. Conclusions

In conclusion, this study showed a prevalence (20%) of subclinical carotid atherosclerosis in black Senegalese patients with RA higher than expected frequency in comparison with the prevalence in Senegalese general population.

We found also a correlation between HT and age (>45 years) and subclinical atherosclerosis, which highlights the importance of the evaluation of traditional CV risk factors in the management of RA.

We showed also, that CV risk was underestimated by mSCORE and the importance of carotid ultrasound for an appropriate stratification of the risk.

However, further studies are needed in sub-Saharan Africa, to evaluate other potential factors such as disease-specific factors that may be induced premature atherosclerosis in patients with RA.

Consent for Publication

Written informed consent for publication was obtained from the patients.

Funding

The authors declare that they have not received another source of funding.

Conflicts of Interest

The authors declare that they have no competing interests.

References

[1] Ruscitti, P., Ciprlani, P., Masedu, F., Romano, S., Berardicurti, O., Liakaouli, V., et al. (2017) Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1-Year Prospective Single Centre Study. *PLoS ONE*, 12, e0170108. [https://doi.org/10.1371/journal.pone.0170108](https://doi.org/10.1371/journal.pone.0170108)
[2] Ndongo, S., Lekpa, F.K., Ka, M.M., Ndialye, N. and Diop, T.M. (2009) Presentation and Severity of Rheumatoid Arthritis in Senegal. *Rheumatology, 48*, 1111-1113. https://doi.org/10.1093/rheumatology/kep178

[3] Taverner, D., Vallve, J.-C., Ferre, R., Paredes, S., Masana, L. and Castro, A. (2018) Variables Associated with Subclinical Atherosclerosis in a Cohort of Rheumatoid Arthritis Patients: Sex-Specific Associations and Differential Effects of Disease Activity and Age. *PLoS ONE, 13*, e0193690. https://doi.org/10.1371/journal.pone.0193690

[4] Arya, R., Escalante, A., Farook, V.S., Restrepo, J.F., Battafarano, D.F., Almelda, M., *et al.* (2018) A Genetic Association Study of Carotid Intima-Media Thickness (CIMT) and Plaque in Mexican Americans and European Americans with Rheumatoid Arthritis. *Atherosclerosis, 271*, 92-101. https://doi.org/10.1016/j.atherosclerosis.2017.11.024

[5] Soubrier, M., Castagné, B., Tatar, Z. and Tournadre, A. (2018) Effects of Treatment on Cardiovascular Risk in Rheumatoid Arthritis. *Revue du Rhumatisme Monographies, 85*, 37-41. https://doi.org/10.1016/j.moonru.2017.11.002

[6] Van Halm, V.P., Peters, M.J., Bos, M., Lems, W.F., Visser, M., *et al.* (2009) Rheumatoid Arthritis versus Diabetes as a Risk Factor for Cardiovascular Disease, a Cross Sectional Study. The CARE Investigation. *Annals of the Rheumatic Diseases, 68*, 1395-1400. https://doi.org/10.1136/ard.2008.094151

[7] Lindhardsen, J., Ahlehoff, O., Gislason, G.H., Madsen, O.R., Olesen, J.B., Torp-Pedersen, C., *et al.* (2011) The Risk of Myocardial Infarction in Rheumatoid Arthritis and Diabetes Mellitus: A Danish Nationwide Cohort Study. *Annals of the Rheumatic Diseases, 70*, 929-934. https://doi.org/10.1136/ard.2010.143396

[8] Dessein, P.H., Norton, G.R., Joffe, B.I., Abdool-Carrim, A.T., Woodiwiss, A.J. and Solomon, A. (2013) Metabolic Cardiovascular Risk Burden and Atherosclerosis in African Black and Caucasian Women with Rheumatoid Arthritis: A Cross-Sectional Study. *Clinical and Experimental Rheumatology, 31*, 53-61.

[9] Solomon, A., Woodiwiss, A.J., Abdool-Carrim, A.T., Stevens, B.A., Norton, G.R. and Dessein, P.H. (2012) The Carotid Artery Atherosclerosis Burden and Its Relation to Cardiovascular Risk Factors in Black and White Africans with Established Rheumatoid Arthritis: A Cross-Sectional Study. *The Journal of Rheumatology, 39*, 1798-1806. https://doi.org/10.3899/jrheum.120073

[10] Solomon, A., Norton, G.R., Woodiwiss, A.J. and Dessein, P.H. (2012) Obesity and Carotid Atherosclerosis in African Black and Caucasian Women with Established Rheumatoid Arthritis: A Cross-Sectional Study. *Arthritis Research & Therapy, 14*, R67. https://doi.org/10.1186/ar3784

[11] Solomon, A., Christian, B.F., Norton, G.R., Woodiwiss, A.J. and Dessein, P.H. (2010) Risk Factor Profiles for Atherosclerotic Cardiovascular Disease in Black and Other Africans with Established Rheumatoid Arthritis. *The Journal of Rheumatology, 37*, 953-960. https://doi.org/10.3899/jrheum.091032

[12] Dessein, P.H., Norton, G.R., Woodiwiss, A.J., Joffe, B.I. and Wolfe, F. (2007) Influence of Nonclassical Cardiovascular Risk Factors on the Accuracy of Predicting Subclinical Atherosclerosis in Rheumatoid Arthritis. *The Journal of Rheumatology, 34*, 943-951.

[13] Dessein, P.H., Tobias, M. and Veller, M.G. (2006) Metabolic Syndrome and Subclinical Atherosclerosis in Rheumatoid Arthritis. *The Journal of Rheumatology, 33*, 2425-2432.

[14] Dessein, P.H., Joffe, B. and Singh, S. (2005) Biomarkers of Endothelial Dysfunction,
Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis. *Arthritis Research & Therapy*, 7, 634-643. [https://doi.org/10.1186/ar1717](https://doi.org/10.1186/ar1717)

[15] Dessein, P.H., Joffe, B., Veller, M.G., Stevens, B.A., Tobias, M., Reddi, K. and Stanwix, A.E. (2005) Traditional and Nontraditional Cardiovascular Risk Factors Are Associated with Atherosclerosis in Rheumatoid Arthritis. *The Journal of Rheumatology*, 32, 435-442.

[16] Ruscitti, P., Magiotta, D.P.E., Macaluso, F., Lacono, D., D’Onofrio, F. and Emmi, G. (2017) Subclinical Atherosclerosis and History of Cardiovascular Events in Italian Patients with Rheumatoid Arthritis. *Medicine*, 96, 42. [https://doi.org/10.1097/MD.0000000000008180](https://doi.org/10.1097/MD.0000000000008180)

[17] Mohan, A., Sada, S. and Katyarmal, D.T. (2014) Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis by Utilizing Carotid Intima-Media Thickness as a Surrogate Marker. *Indian Journal of Medical Research*, 140, 379-386.

[18] Mulumba, C., Lebughe, P., Mbuyi-Muamba, J.M., Makulo, J.B., Lepira, F., Mukaya, J., *et al.* (2019) Prevalence of Subclinical Atherosclerosis in Rheumatoid Arthritis at the University Hospital of Kinshasa. *BMC Rheumatology*, 3, 37. [https://doi.org/10.1186/s41927-019-0085-4](https://doi.org/10.1186/s41927-019-0085-4)

[19] Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham III, C.O., *et al.* (2010) Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. *Annals of the Rheumatic Diseases*, 69, 1580-1588. [https://doi.org/10.1136/ard.2010.138461](https://doi.org/10.1136/ard.2010.138461)

[20] Wells, G., Becker, J.-C., Teng, J., Dougados, M., Schiff, M., Smolen, J., Aletaha, D. and van Riel, P.L.C.M. (2009) Validation of the 28-Joint Disease Activity Score (DAS28) and European League against Rheumatism Response Criteria Based on C-Reactive Protein against Disease Progression in Patients with Rheumatoid Arthritis and Comparison with the DAS28 Based on Erythrocyte Sedimentation Rate. *Annals of the Rheumatic Diseases*, 68, 954-960. [https://doi.org/10.1136/ard.2007.084459](https://doi.org/10.1136/ard.2007.084459)

[21] Agca, R., Heslinga, S.C., Rollefastad, S., *et al.* (2016) EULAR Recommendations for Cardiovascular Disease Risk Management in Patients with Rheumatoid Arthritis and Other Forms of Inflammatory Joint Disorders: 2015/2016 Update. *Annals of the Rheumatic Diseases*, 76, 17-28. [https://doi.org/10.1136/annrheumdis-2016-209775](https://doi.org/10.1136/annrheumdis-2016-209775)

[22] Corrales, A., Parra, J.A., Gonzalez-Juanatey, C., Rueda-Gotor, J., Blanco, R., Llorca, J., *et al.* (2013) Cardiovascular Risk Stratification in Rheumatic Diseases: Carotid Ultrasound Is More Sensitive than Coronary Artery Calcification Score to Detect Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. *Annals of the Rheumatic Diseases*, 72, 1764-1770. [https://doi.org/10.1136/annrheumdis-2013-203688](https://doi.org/10.1136/annrheumdis-2013-203688)

[23] Combe, B., Benessiano, J., Berenbaum, F., Cantagrel, A. and Daurès, J.-P. (2017) The ESPOIR Cohort: A Ten-Year Follow-Up of Early Arthritis in France. Methodology and Baseline Characteristics of the 813 Included Patients. *Revue du Rhumatisme*, 74, 838-844. [https://doi.org/10.1016/j.rhum.2007.06.003](https://doi.org/10.1016/j.rhum.2007.06.003)

[24] Bezza, A., Ghozlani, I., Rezqui, A., Achemial, L. and Mounach, A. (2012) Diagnosis of Onset Arthritis Rheumatoid. *Revue Marocaine de Rhumatologie*, 19, 10-13.

[25] Skeoch, S. and Bruce, I.N. (2015) Atherosclerosis in Rheumatoid Arthritis: Is It All about Inflammation? *Nature Reviews Rheumatology*, 11, 390-400. [https://doi.org/10.1038/nrrheum.2015.40](https://doi.org/10.1038/nrrheum.2015.40)
[26] Ambrosino, P., Lupoli, R., Di Minno, A., Tasso, M., Peluso, R. and Di Minno, M.N. Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis: A Meta-Analysis of Literature Studies. *Thrombosis and Haemostasis, 113*, 916-930. https://doi.org/10.1160/TH14-11-0921

[27] Rodriguez, L.R., Lopez-Mejias, R. and Martin, J. (2012) Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis. *Mediators of Inflammation, 2012*, Article ID: 574817. https://doi.org/10.1155/2012/574817

[28] Babaka, K., Sarr, S.A., Kane, A.D., Mbaye, A., Ngaiide, A.A., et al. (2016) Prevalence of Atherosclerotic Plaques in Semi-Rural Gueoul, Senegal: Survey of 1411 Subjects. *Journal des Maladies Vasculaires, 41*, 176-181. https://doi.org/10.1016/j.jmv.2016.03.005

[29] Peters, M.J., Symmons, D.P., McCarey, D., Dijkmans, B.A., Nicola, P., Kvien, T.K., et al. (2010) EULAR Evidence-Based Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Forms of Inflammatory Arthritis. *Annals of the Rheumatic Diseases, 69*, 325-331. https://doi.org/10.1136/ard.2009.113696